Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

Gethin R. Ellis, Angus K. Nightingale, Daniel J. Blackman, Richard A. Anderson, Catherine Mumford, Graham Timmins, Derek Lang, Simon K. Jackson, Michael D. Penney, Malcolm J. Lewis, Michael P. Frenneaux, Jayne Morris-Thurgood

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.
Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalEuropean Journal of Heart Failure
Issue number2
Publication statusPublished - Mar 2002


  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Benzimidazoles
  • Blood Pressure
  • Brachial Artery
  • Chronic Disease
  • Drug Therapy, Combination
  • Endothelium, Vascular
  • Exercise Tolerance
  • Female
  • Follow-Up Studies
  • Heart Failure
  • Heart Rate
  • Humans
  • Lipid Peroxidation
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain
  • Oxidative Stress
  • Stroke Volume
  • Tetrazoles
  • Time Factors
  • Treatment Outcome

Cite this